Clinical trials using myostatin inhibitors have covered both DMD, the milder phenotype Becker Muscular Dystrophy (BMD) and LGMD, idiopathic inflammatory myopathies (sporadic inclusion body myositis, sIBM), cancer patients, COPD and a geriatric patient population (sarcopenia and weak fallers) (Table 2 and detailed overview in Supplementary Table S2). Here, MSTN is linked to sarcopenia.